Patent · US Active

Compounds

US9487528B2 · kind B2 · utility

0Cited by
5References
27Claims
0Family size

Assignee

Inventors

Key dates

Filing dateJun 5, 2015
Grant dateNov 8, 2016
Priority date
Expiry dateJun 5, 2035

Classification

  • Technology area (CPC A)Human Necessities
  • CPC primaryA61K9/008
  • WIPO fieldPharmaceuticals
  • WIPO sectorChemistry

Abstract

Compounds of formula (I), described herein, exhibit human neutrophil elastase inhibitory properties, and are useful for the treatment of diseases and conditions in which HNE is implicated.

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.